Stay updated on Nivolumab & Lenvatinib in HCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab & Lenvatinib in HCC Clinical Trial page.

Latest updates to the Nivolumab & Lenvatinib in HCC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now displays a newer software/site revision identifier (“Revision: v3.5.3”) rather than the previous one (“Revision: v3.5.2”). This reflects a version update of the ClinicalTrials.gov page tooling rather than any change to the underlying study information.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check55 days agoChange DetectedAdded the hepatocellular carcinoma term and a Genetic and Rare Diseases Information Center resource; updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page's revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded Revision: v3.4.2 and removed older notices about government funding and NIH Clinical Center operating status. These are administrative updates that do not modify the study details.SummaryDifference0.4%

- Check97 days agoChange DetectedA new government funding notice was added to the page to inform users about potential updates and refer them to cc.nih.gov and opm.gov. The site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Nivolumab & Lenvatinib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab & Lenvatinib in HCC Clinical Trial page.